Anzupgo (delgocitinib) / Japan Tobacco, LEO Pharma, Rohto Pharma - LARVOL DELTA

Treatment with delgocitinib cream improves health-related quality of life in adolescents with moderate to severe chronic hand eczema: Results from DELTA TEEN; a randomized, double-blind, vehicle-controlled phase 3 trial (EADV 2026) - P3 | "Conclusions Treatment with delgocitinib cream resulted in considerable improvement in HRQoL in adolescents with moderate to severe CHE. This was consistent with the findings in adults and suggests that delgocitinib cream may represent a valuable treatment option in this population."

Clinical • HEOR • P3 data • Contact Dermatitis • Dermatology • Immunology

Long-Term Safety of JAK and TYK inhibitors in the treatment of Psoriasis, Psoriatic Arthritis, and Atopic Dermatitis: A Systematic Review (EADV 2026) - "The search strategy combined terms related to Janus kinase inhibitors, including upadacitinib, abrocitinib, baricitinib, ruxolitinib, delgocitinib, tofacitinib, and "Janus kinase inhibitor"; TYK inhibitors, including deucravacitinib; adverse event terminology (e.g., adverse events, adverse effects, side effects, and safety); and disease indications (PsO, PsA, and AD). Conclusions JAK and TYK inhibitors demonstrate favorable efficacy with substantial rates of clinical response across PsO, PsA and AD, accompanied by a low incidence of serious adverse events. These findings support the overall benefit-risk profile of JAK and TYK inhibitors in immune-mediated inflammatory diseases while underscoring the importance of continued long-term safety monitoring in real-world populations."

Clinical • Review • Atopic Dermatitis • Cardiovascular • Dermatitis • Dermatology • Herpes Zoster • Immunology • Infectious Disease • Inflammatory Arthritis • Musculoskeletal Diseases • Psoriasis • Psoriatic Arthritis • Respiratory Diseases • Rheumatology • Seronegative Spondyloarthropathies • Varicella Zoster • Venous Thromboembolism

Rapid improvement in signs and symptoms with topical delgocitinib cream 20 mg/g in mixed atopic and irritant chronic hand eczema: a case report (EADV 2026) - "Delgocitinib cream 20 mg/g demonstrated a rapid and clinically meaningful response in a severe case of chronic hand eczema unresponsive to conventional therapies. The early onset of action within the first week supports its potential role as an effective topical treatment option for difficult to treat chronic hand eczema."

Case report • Clinical • Contact Dermatitis • Dermatitis • Dermatology • Immunology • Infectious Disease • Inflammation • Pruritus

Evaluation of delgocitinib cream in chronic hand eczema: Early Real-World Experience (EADV 2026) - "One experienced recurrent irritant-type flares requiring oral prednisolone, and another discontinued treatment after two tubes due to perceived lack of efficacy. The absence of COVID‑19 or nasopharyngitis likely reflects sample size and differing background infection rates (DELTA studies conducted during the COVID-19 pandemic). The observed plateau in HECSI improvement between weeks 4 and 16 may help clinicians counsel patients on expected treatment timelines and set realistic goals."

Clinical • Real-world • Real-world evidence • Contact Dermatitis • Dermatology • Immunology • Infectious Disease • Novel Coronavirus Disease

Topical pan-JAK inhibition with delgocitinib 20mg/g cream in inflammatory diseases of the nails: a real-life case series (EADV 2026) - "While topical data exist for molecules such as tofacitinib and ruxolitinib, evidence on delgocitinib, the newest topical pan-JAK inhibitor, remains limited, particularly regarding its off-label use in nail disorders...Its favorable cream vehicle formulation — non-greasy and rapidly absorbed — likely contributes to good patient adherence and tolerability, particularly in such a challenging anatomical site. In line with the shared pathogenic role of JAK-STAT signaling and existing evidence with other pan-JAK inhibitors such as tofacitinib, these findings further support the potential of this class of agents in improving inflammatory keratotic nail disorders and warrant confirmation in controlled clinical studies."

Clinical • Dermatopathology • Inflammation • Lichen Planus • Psoriasis • Pustular Psoriasis

Comprehensive Assessment of Skin Barrier Dysfunction in Chronic Hand Eczema in Patients Eligible for Delgocitinib: A Non-Invasive Comparative Study (EADV 2026) - "Electrical impedance parameters showed variability, with lower mix values (5.39 vs 6.28) and markedly lower Z values (142.2 vs 329.1), No consistent pattern was observed for SCH. Conclusions Chronic hand eczema is associated with multidimensional alterations in skin barrier function, supporting the central role of barrier dysfunction and highlighting the potential of non-invasive biomarkers for objective disease characterization and for guiding and monitoring response to targeted therapies such as delgocitinib."

Clinical • Non-invasive • Contact Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation

Molecular Transcriptomics-Guided Treatment Selection in a Case of Palmar Psoriasis (EADV 2026) - "Oral alitretinoin did not lead to relevant improvement. Oral ciclosporin resulted in a partial regression of the skin lesions, but no sustained complete remission. Additionally, topical delgocitinib cream as an add-on therapy also failed to achieve full symptom control...Based on this molecular profile, treatment with the IL-17A/F inhibitor bimekizumab was initiated subcutaneously...In this case, NanoString-based molecular profiling identified a Th17-dominant signature in a patient with diagnostically challenging chronic palmar inflammatory dermatosis and successfully guided treatment selection with IL-17A/F inhibition. This case supports the potential value of transcriptomic profiling as a practical decision-support tool in difficult to treat palmoplantar inflammatory dermatoses cases."

Clinical • Conjunctivitis • Contact Dermatitis • Dermatology • Immunology • Infectious Disease • Ocular Infections • Ocular Inflammation • Ophthalmology • Psoriasis • IL17A

Treating successfully and keeping long-term remission in a patient with chronic hand eczema using delgocitinib (EADV 2026) - "Case Presentation A 47- year- old Caucasian female patient presented with redness, scaling, fissures, intense itching, and pain on both palms for the last 5 years, resistant to topical corticosteroids, calcineurin inhibitors, cyclosporine and alitretinoin. Our patient maintained the remission of disease for over a year by using the cream as a maintenance dose three times a week. Case reports like these suggest that studies with larger number of patients could in the future, help confirm the above benefits in daily clinical practice."

Clinical • Contact Dermatitis • Dermatology • Immunology • Inflammation • Pruritus

A review of pediatric chronic hand eczema with a focus on risk factors, allergens, and management (EADV 2026) - "Topical calcineurin inhibitors and phototherapy offer steroid-sparring alternatives, while topical JAK inhibitors (e.g., delgocitinib) represent a promising emerging class with active trials in adolescents...Alitretinoin, methotrexate, and cyclosporine are used cautiously off-label. Dupilumab, approved for pediatric atopic dermatitis (AD), has emerged as a favoured first-line systemic therapy for P-CHE demonstrating efficacy and safety...Existing data is primarily derived from limited subgroup analyses within adult predominant trials, or from patients with atopic hand dermatitis enrolled within larger AD studies. Future research must address these gaps to inform guideline development and prioritize international consensus, with the goal of improving patient outcomes."

Clinical • Review • Contact Dermatitis • Dermatitis • Dermatology • Immunology • Pediatrics

Pediatric-Origin Disease, Adult-Valued Targets: A Systematic Review of the DELTA TEEN Paradigm in Chronic Hand Eczema (EADV 2026) - "Introduction Topical pan-JAK inhibitor that is Delgocitinib cream was found to be effective in treating from moderate to severe chronic hand eczema (CHE) in adolescents in the recently published study of DELTA TEEN...This can lead to more persistent dosing that changes overall long-term safety concerns. Because of this, it's not enough to just use adult dosing and schedules, in the pediatric patients they need their own dosing measures and treatment timelines that take into account with their particular patterns of drug response and usage."

Clinical • Review • Contact Dermatitis • Dermatology • Herpes Zoster • Immunology • Infectious Disease • Pediatrics • Varicella Zoster • JAK1 • TYK2

Rapid Improvement with Topical Delgocitinib in Severe Refractory Atopic Dermatitis: A Case Report (EADV 2026) - "The patient was first treated with dupilumab, which resulted in partial improvement but persistent active lesions and pruritus. Therapy was subsequently switched to the oral JAK inhibitor abrocitinib, leading to an initial clinical response followed by secondary loss of efficacy...Conclusion The addition of topical delgocitinib to systemic upadacitinib therapy resulted in rapid and clinically significant improvement in a patient with severe refractory AD. This case supports further investigation of combined topical and systemic JAK inhibition as a potential therapeutic strategy in difficult-to-treat AD."

Case report • Clinical • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Pruritus • IL13

Delgocitinib cream provides rapid improvements in itch and pain symptoms in adolescents with moderate to severe chronic hand eczema: Results from DELTA TEEN (EADV 2026) - P3 | "* P <0.05, ** P <0.01, *** P < 0.001 (ANCOVA). Abbreviations: ANCOVA: Analysis of covariance; HESD: hand eczema symptom diary; IMP: Investigational medicinal product."

Contact Dermatitis • Dermatology • Immunology • Inflammation • Pain

Health-Related Quality of Life and work productivity improvements with topical delgocitinib vs oral alitretinoin in Chronic Hand Eczema: phase 3 DELTA FORCE results (EADV 2026) - P3 | "Furthermore, work productivity and daily activity impairment improved to a larger extent. These findings indicate that delgocitinib cream may serve as a valuable topical treatment option for patients with moderate to severe CHE in routine care, prior to the need for systemic therapy."

Clinical • HEOR • P3 data • Contact Dermatitis • Dermatology • Immunology

Real-world effectiveness of delgocitinib cream in adults with moderate to severe Chronic Hand Eczema: interim analysis after 8 weeks of treatment in the German REACHED study (EADV 2026) - "Conclusions Interim results from the REACHED demonstrate show short-term effectiveness of delgocitinib cream in adults with moderate to severe CHE, with considerable improvements in mPGA, HECSI, DLQI, and NRS scores after the first 8 weeks of treatment. This interim analysis provides early real-world evidence supporting the use of delgocitinib cream in CHE management and complements clinical data from the DELTA trials."

Clinical • Real-world • Real-world effectiveness • Real-world evidence • Contact Dermatitis • Dermatology • Immunology • Inflammation

Real-world effectiveness of topical delgocitinib in chronic hand eczema: a case series (EADV 2026) - "Conclusions In this real-world Italian case series, topical delgocitinib demonstrated rapid onset of action on pruritus and sustained clinical improvement in patients with recalcitrant CHE, confirming and extending evidence from clinical trials. These findings suggest that delgocitinib may represent a valid therapeutic for patients who failed corticosteroid or need a steroid-sparing first-line approach to optimize long-term outcomes."

Clinical • Real-world • Real-world effectiveness • Real-world evidence • Contact Dermatitis • Dental Disorders • Dermatology • Immunology • Pruritus

Sustained Health-related Quality of Life improvements with delgocitinib 20 mg/g cream in Chronic Hand Eczema – results from the phase 3 open-label extension DELTA 3 trial (EADV 2026) - P3 | "Furthermore, work productivity loss and daily activity impairment scores decreased, with mean changes from baseline of -25.4 (95% CI: -29.0, -21.9) and -33.3 (95% CI: -35.8, -30.7), respectively (p<0.0001 for both) (Table 1). Conclusions Improvements in HRQoL, work productivity, and daily activity impairment demonstrated after 16 weeks of continuous twice-daily treatment with delgocitinib cream were maintained after an additional 36 weeks of as-needed treatment in patients with moderate to severe CHE."

Clinical • HEOR • P3 data • Contact Dermatitis • Dermatology • Immunology

Delgocitinib cream reduces patient-reported disease severity in adults with moderate to severe Chronic Hand Eczema: pooled analysis of the Phase 3 DELTA 1 and DELTA 2 trials (EADV 2026) - P3 | "When PGI‑S HESD (see Table 1) was extended to include scores 0/1, a significant difference was observed from Week 2 (43.7% [n=275] vs. 31.0% [n=98]; p<0.001) and continued through Week 16 (60.6% [n=382] vs. 32.3% [n=102]; p<0.001). Conclusions Treatment with delgocitinib cream 20 mg/g twice daily resulted in rapid and sustained reductions in patient-reported severity of CHE during the DELTA 1 and 2 pivotal trials, as indicated by improvements in PaGA, PGI-C, and PGI-S."

P3 data • Retrospective data • Contact Dermatitis • Dermatology • Immunology • Inflammation

Hand eczema and its subtypes (EADV 2026) - "Finally, a stepped-care management approach will be outlined, from prevention and patient education to topical therapy (topical corticosteroids and calcineurin inhibitors), before advancing to therapies for refractory cases (phototherapy, alitretinoin, oral corticosteroids, cyclosporin, azathioprine, methotrexate, acitretin) and the topical pan-JAK inhibitor delgocitinib. Investigative work-up and exposure identification: participants will focus on patient history and diagnostic tools (patch testing, prick testing) to detect relevant triggers. Application of therapeutic algorithm: attendees will master a stepwise treatment protocol, progressing from basic therapy (emollients / skin care, exposure reduction) to topical and systemic therapy, focusing on treatment choice through clinical cases and gaining confidence of using targeted therapies like delgocitinib."

Contact Dermatitis • Dental Disorders • Dermatology • Immunology • Urticaria

Delgocitinib Cream for Chronic Hand Dermatitis: Efficacy, Safety and Clinical Application. (PubMed, Skin Therapy Lett) - "Safety data reveal minimal systemic absorption, no steroid-associated skin atrophy, and a favorable tolerability profile without box warnings. This review examines the pathophysiology of CHD and the clinical evidence supporting delgocitinib as an effective, steroid-sparing therapeutic option."

Journal • Review • Contact Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation • Pain • Pruritus • JAK1 • JAK3 • TYK2

Topical pan-JAK inhibition in early mycosis fungoides: successful clinical response with delgocitinib - Clinical observation in the context of limited prospective evidence for topical application (ADO 2026) - No abstract available

Clinical • Cutaneous T-cell Lymphoma • Dermatology • Mycosis Fungoides • Oncology

Topical pan-JAK inhibition in early mycosis fungoides: successful clinical response with delgocitinib - Clinical observation in the context of limited prospective evidence for topical application (ADO 2026) - No abstract available

Clinical • Cutaneous T-cell Lymphoma • Dermatology • Mycosis Fungoides • Oncology

LEO Pharma receives positive CHMP opinion recommending Anzupgo (delgocitinib) cream for adolescents with moderate to severe chronic hand eczema in the EU (LEO Pharma Press Release) - "The CHMP opinion is supported by results from DELTA TEEN, a 16-week, phase 3, randomized, double-blind, vehicle-controlled, parallel-group, multi-site trial evaluating twice-daily applications of Anzupgo compared with cream vehicle in adolescents aged 12 to 17 years with moderate to severe chronic hand eczema for whom topical corticosteroids are inadequate or inappropriate."

CHMP • Dermatology

DelVito: Topical Delgocitinib for Facial Vitiligo (clinicaltrials.gov) - P2 | N=12 | Active, not recruiting | Sponsor: Lone Skov

New P2 trial • Dermatology • Immunology • Vitiligo

Leo Pharma's 'ANZUPGO (ingredient name delgocitinib)'…[was] also recognized as appropriate for coverage for the treatment of chronic hand eczema (Chosun Biz)

Reimbursement • Atopic Dermatitis

Janus Kinase Inhibitors in Atopic Dermatitis: A Global Bibliometric Analysis (2015-2025). (PubMed, J Clin Pract Res) - "Pruritus and alopecia areata (AA) were the most frequently co-occurring keywords alongside atopic dermatitis, while delgocitinib and abrocitinib were the most frequently investigated JAK inhibitors. Janus kinase (JAK) inhibitors represent one of the most effective and trending therapeutic classes in AD. These agents are not only highly effective for AD but also show promising efficacy in other dermatologic conditions, such as AA."

Journal • Alopecia • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Pruritus